Sector News

Becton Dickinson to buy CareFusion for $12bn

October 8, 2014
Life sciences

Medical devices giant Becton Dickinson (BD) has agreed to buy automation and infection prevention specialist CareFusion for over $12 billion (£7.5 billion) in a mixture of shares and borrowed cash.

CareFusion develops technology for reducing drug dispensing errors by automation, and for preventing and detecting infections.

BD says that Carefusion’s products are complementary to its own ranges, and its distribution infrastructure will allow the merged company to increase global sales and cut supply chain costs.

The move follows other consolidation between major players in the medical devices segment, including Medtronic’s $43 billion purchase of Covidien in June.

Source: Chemistry World

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]